476 related articles for article (PubMed ID: 31904116)
1. Targeting Wnt/β-catenin and PI3K/Akt/mTOR pathways in T-cell acute lymphoblastic leukemia.
Evangelisti C; Chiarini F; Cappellini A; Paganelli F; Fini M; Santi S; Martelli AM; Neri LM; Evangelisti C
J Cell Physiol; 2020 Jun; 235(6):5413-5428. PubMed ID: 31904116
[TBL] [Abstract][Full Text] [Related]
2. Are Wnt/β-Catenin and PI3K/AKT/mTORC1 Distinct Pathways in Colorectal Cancer?
Prossomariti A; Piazzi G; Alquati C; Ricciardiello L
Cell Mol Gastroenterol Hepatol; 2020; 10(3):491-506. PubMed ID: 32334125
[TBL] [Abstract][Full Text] [Related]
3. Tankyrase Inhibition Blocks Wnt/β-Catenin Pathway and Reverts Resistance to PI3K and AKT Inhibitors in the Treatment of Colorectal Cancer.
Arqués O; Chicote I; Puig I; Tenbaum SP; Argilés G; Dienstmann R; Fernández N; Caratù G; Matito J; Silberschmidt D; Rodon J; Landolfi S; Prat A; Espín E; Charco R; Nuciforo P; Vivancos A; Shao W; Tabernero J; Palmer HG
Clin Cancer Res; 2016 Feb; 22(3):644-56. PubMed ID: 26224873
[TBL] [Abstract][Full Text] [Related]
4. Small-molecule inhibition of CBP/catenin interactions eliminates drug-resistant clones in acute lymphoblastic leukemia.
Gang EJ; Hsieh YT; Pham J; Zhao Y; Nguyen C; Huantes S; Park E; Naing K; Klemm L; Swaminathan S; Conway EM; Pelus LM; Crispino J; Mullighan CG; McMillan M; Müschen M; Kahn M; Kim YM
Oncogene; 2014 Apr; 33(17):2169-78. PubMed ID: 23728349
[TBL] [Abstract][Full Text] [Related]
5. Improving nelarabine efficacy in T cell acute lymphoblastic leukemia by targeting aberrant PI3K/AKT/mTOR signaling pathway.
Lonetti A; Cappellini A; Bertaina A; Locatelli F; Pession A; Buontempo F; Evangelisti C; Evangelisti C; Orsini E; Zambonin L; Neri LM; Martelli AM; Chiarini F
J Hematol Oncol; 2016 Oct; 9(1):114. PubMed ID: 27776559
[TBL] [Abstract][Full Text] [Related]
6. Inhibition of the Wnt/β-catenin signaling pathway improves the anti-tumor effects of sorafenib against hepatocellular carcinoma.
Lin HH; Feng WC; Lu LC; Shao YY; Hsu CH; Cheng AL
Cancer Lett; 2016 Oct; 381(1):58-66. PubMed ID: 27431312
[TBL] [Abstract][Full Text] [Related]
7. Synergistic effects of selective inhibitors targeting the PI3K/AKT/mTOR pathway or NUP214-ABL1 fusion protein in human Acute Lymphoblastic Leukemia.
Simioni C; Ultimo S; Martelli AM; Zauli G; Milani D; McCubrey JA; Capitani S; Neri LM
Oncotarget; 2016 Nov; 7(48):79842-79853. PubMed ID: 27821800
[TBL] [Abstract][Full Text] [Related]
8. The Wnt/β-catenin and PI3K/Akt signaling pathways promote EMT in gastric cancer by epigenetic regulation via H3 lysine 27 acetylation.
Song Y; Li ZX; Liu X; Wang R; Li LW; Zhang Q
Tumour Biol; 2017 Jul; 39(7):1010428317712617. PubMed ID: 28671020
[TBL] [Abstract][Full Text] [Related]
9. Peruvoside targets apoptosis and autophagy through MAPK Wnt/β-catenin and PI3K/AKT/mTOR signaling pathways in human cancers.
Reddy D; Kumavath R; Tan TZ; Ampasala DR; Kumar AP
Life Sci; 2020 Jan; 241():117147. PubMed ID: 31830480
[TBL] [Abstract][Full Text] [Related]
10. Growth inhibition and suppression of the mTOR and Wnt/β-catenin pathways in T-acute lymphoblastic leukemia by rapamycin and MYCN depletion.
Kong D; Fan S; Sun L; Chen X; Zhao Y; Zhao L; Guo Z; Li Y
Hematol Oncol; 2021 Apr; 39(2):222-230. PubMed ID: 33300153
[TBL] [Abstract][Full Text] [Related]
11. Phospholipase D1 Inhibition Linked to Upregulation of ICAT Blocks Colorectal Cancer Growth Hyperactivated by Wnt/β-Catenin and PI3K/Akt Signaling.
Kang DW; Lee BH; Suh YA; Choi YS; Jang SJ; Kim YM; Choi KY; Min DS
Clin Cancer Res; 2017 Dec; 23(23):7340-7350. PubMed ID: 28939743
[No Abstract] [Full Text] [Related]
12. The β-catenin/CBP-antagonist ICG-001 inhibits pediatric glioma tumorigenicity in a Wnt-independent manner.
Wiese M; Walther N; Diederichs C; Schill F; Monecke S; Salinas G; Sturm D; Pfister SM; Dressel R; Johnsen SA; Kramm CM
Oncotarget; 2017 Apr; 8(16):27300-27313. PubMed ID: 28460484
[TBL] [Abstract][Full Text] [Related]
13. Canagliflozin, a SGLT-2 inhibitor, relieves ER stress, modulates autophagy and induces apoptosis in irradiated HepG2 cells: Signal transduction between PI3K/AKT/GSK-3β/mTOR and Wnt/β-catenin pathways;
Abdel-Rafei MK; Thabet NM; Rashed LA; Moustafa EM
J Cancer Res Ther; 2021; 17(6):1404-1418. PubMed ID: 34916371
[TBL] [Abstract][Full Text] [Related]
14. A loss-of-function genetic screening reveals synergistic targeting of AKT/mTOR and WTN/β-catenin pathways for treatment of AML with high PRL-3 phosphatase.
Zhou J; Toh SH; Chan ZL; Quah JY; Chooi JY; Tan TZ; Chong PSY; Zeng Q; Chng WJ
J Hematol Oncol; 2018 Mar; 11(1):36. PubMed ID: 29514683
[TBL] [Abstract][Full Text] [Related]
15. Activation of WNT/β-catenin signaling results in resistance to a dual PI3K/mTOR inhibitor in colorectal cancer cells harboring PIK3CA mutations.
Park YL; Kim HP; Cho YW; Min DW; Cheon SK; Lim YJ; Song SH; Kim SJ; Han SW; Park KJ; Kim TY
Int J Cancer; 2019 Jan; 144(2):389-401. PubMed ID: 29978469
[TBL] [Abstract][Full Text] [Related]
16. miRNA-125b regulates apoptosis of human non-small cell lung cancer via the PI3K/Akt/GSK3β signaling pathway.
Wang Y; Zhao M; Liu J; Sun Z; Ni J; Liu H
Oncol Rep; 2017 Sep; 38(3):1715-1723. PubMed ID: 28713974
[TBL] [Abstract][Full Text] [Related]
17. [Molecular mechanisms of resistance to phosphatidyl inositol 3-kinase inhibitors in triple-negative breast cancer cells].
Zhang WL; Ma WJ; Chen S; Wu XZ; Zhang HR; Zhang JH
Zhonghua Zhong Liu Za Zhi; 2016 Aug; 38(8):578-88. PubMed ID: 27531477
[TBL] [Abstract][Full Text] [Related]
18. Dual inhibition of class IA phosphatidylinositol 3-kinase and mammalian target of rapamycin as a new therapeutic option for T-cell acute lymphoblastic leukemia.
Chiarini F; Falà F; Tazzari PL; Ricci F; Astolfi A; Pession A; Pagliaro P; McCubrey JA; Martelli AM
Cancer Res; 2009 Apr; 69(8):3520-8. PubMed ID: 19351820
[TBL] [Abstract][Full Text] [Related]
19. Harnessing the PI3K/Akt/mTOR pathway in T-cell acute lymphoblastic leukemia: eliminating activity by targeting at different levels.
Bressanin D; Evangelisti C; Ricci F; Tabellini G; Chiarini F; Tazzari PL; Melchionda F; Buontempo F; Pagliaro P; Pession A; McCubrey JA; Martelli AM
Oncotarget; 2012 Aug; 3(8):811-23. PubMed ID: 22885370
[TBL] [Abstract][Full Text] [Related]
20. The pan-PI3K inhibitor GDC-0941 activates canonical WNT signaling to confer resistance in TNBC cells: resistance reversal with WNT inhibitor.
Tzeng HE; Yang L; Chen K; Wang Y; Liu YR; Pan SL; Gaur S; Hu S; Yen Y
Oncotarget; 2015 May; 6(13):11061-73. PubMed ID: 25857298
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
